H.R.3715 - Personal Drug Importation Fairness Act of 2013113th Congress (2013-2014)
|Sponsor:||Rep. Ellison, Keith [D-MN-5] (Introduced 12/12/2013)|
|Committees:||House - Energy and Commerce|
|Latest Action:||12/13/2013 Referred to the Subcommittee on Health.|
This bill has the status Introduced
Here are the steps for Status of Legislation:
Text: H.R.3715 — 113th Congress (2013-2014)All Bill Information (Except Text)
There is one version of the bill.
Introduced in House (12/12/2013)
Formatting necessary for an accurate reading of this legislative text may be shown by tags (e.g., <DELETED> or <BOLD>) or may be missing from this TXT display. For complete and accurate display of this text, see the PDF or HTML/XML.
[Congressional Bills 113th Congress] [From the U.S. Government Printing Office] [H.R. 3715 Introduced in House (IH)] 113th CONGRESS 1st Session H. R. 3715 To reduce prescription drug costs by allowing the importation and reimportation of certain drugs. _______________________________________________________________________ IN THE HOUSE OF REPRESENTATIVES December 12, 2013 Mr. Ellison (for himself and Mr. Rohrabacher) introduced the following bill; which was referred to the Committee on Energy and Commerce _______________________________________________________________________ A BILL To reduce prescription drug costs by allowing the importation and reimportation of certain drugs. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Personal Drug Importation Fairness Act of 2013''. SEC. 2. REDUCING PRESCRIPTION DRUG COSTS BY ALLOWING CERTAIN DRUGS TO BE IMPORTED OR REIMPORTED. (a) In General.--Notwithstanding any provision of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.), a drug may be imported into the United States, and may be reimported into the United States by a person other than the drug's manufacturer, if the drug-- (1) has the same active ingredients, route of administration, and strength as a prescription drug approved under chapter V of such Act (21 U.S.C. 351 et seq.); (2) may be lawfully marketed in, and is imported or reimported from, a qualified country; (3) is dispensed by a licensed pharmacist; (4) is shipped directly to, or is imported by, the ultimate consumer from the qualified country; (5) is shipped or imported in quantities that do not exceed a 90-day supply; and (6) is accompanied by a copy of a valid prescription. (b) Definitions.--In this Act: (1) The term ``drug'' has the meaning given to such term in section 201 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321), except that such term excludes any controlled substance (as defined in section 102 of the Controlled Substances Act (21 U.S.C. 802)). (2) The term ``prescription drug'' means a drug subject to section 503(b)(1) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353(b)(1)). (3) The term ``qualified country'' means a country that-- (A) is Australia, Canada, Israel, Japan, New Zealand, Switzerland, South Africa, a member-state of the European Union, or a country in the European Economic Area; and (B) is determined by the Commissioner of Food and Drugs to have standards for ensuring the safety and effectiveness of drugs that are at least as protective as such standards in the United States. <all>